XPRIZE Awards $1 Million to Mitochondrial Drug Team for Aging Research

How Does Elamipretide Target Cellular Aging?

Mighty Therapeutics and the University of Washington have received a $1 million grant from XPRIZE to advance research on elamipretide, a drug targeting mitochondrial function. The funding will support the design of a larger clinical trial focused on older adults, building on promising pilot data. This award is part of XPRIZE’s Healthspan competition, which aims to extend healthy human lifespan through innovative scientific approaches.

The team plans to use early results showing elamipretide’s potential to improve cellular energy production to shape a more extensive study. Mitochondrial decline is closely linked to aging and age-related diseases, making it a key target for interventions. By focusing on older populations, the researchers hope to determine whether the drug can delay or reduce the onset of frailty and functional decline. The pilot data indicated improvements in muscle fatigue and biomarkers of mitochondrial health, providing a foundation for the next phase.

What Outcomes Will the Larger Trial Measure?

Elamipretide works by stabilizing cardiolipin, a phospholipid essential for mitochondrial structure and function. As people age, cardiolipin becomes damaged, leading to inefficient energy production and increased oxidative stress. By binding to this molecule, elamipretide helps restore mitochondrial efficiency, which may improve tissue resilience. Preclinical models have shown enhanced exercise tolerance and reduced inflammation, supporting its potential in humans. The University of Washington’s expertise in mitochondrial biology complements Mighty Therapeutics’ clinical development experience, creating a strong translational partnership.

The upcoming trial will assess physical performance, including walking speed and grip strength, as primary indicators of healthspan. Secondary endpoints will include mitochondrial activity in blood cells, levels of inflammatory markers, and patient-reported outcomes on fatigue and quality of life. Researchers aim to enroll several hundred participants aged 65 and older across multiple sites. Success could pave the way for regulatory approval and broader use in aging populations. The study design incorporates feedback from earlier trials to improve statistical power and relevance to real-world function.

What is elamipretide and how is it administered? Elamipretide is a small peptide drug designed to penetrate mitochondria and protect cardiolipin. It is typically given via intravenous infusion or subcutaneous injection in clinical trials.

Frequently Asked Questions

Why focus on older adults in this trial? Older adults experience the most pronounced mitochondrial decline, making them ideal for testing whether interventions can meaningfully extend healthspan and delay age-related deterioration.

How does this award fit into the XPRIZE Healthspan competition? The $1 million milestone award recognizes teams with strong preliminary data, enabling them to scale up studies that could lead to breakthroughs in longevity science.